References
- Fukuda K , StrausSE, HickieI et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 121(12) , 953–959 (1994).
- De Becker P , RoeykensJ, ReyndersM et al. Exercise capacity in chronic fatigue syndrome. Arch. Intern. Med. 160(21) , 3270–3277 (2000).
- Constant EL , AdamS, GillainB et al. Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls. Clin. Neurol. Neurosurg. 113(4) , 295–302 (2011).
- Snell CR , VannessJM, StrayerDR et al. Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS). In Vivo 19(2) , 387–390 (2005).
- Wechsler D . Wechsler Adult Intelligence Scale (3rd Edition). The Psychological Corporation, TX, USA (1997).
- Lorusso L , MikhaylovaSV, CapelliE et al. Immunological aspects of chronic fatigue syndrome. Autoimmun. Rev. 8(4) , 287–291 (2009).
- Morris G , MaesM. A neuro–immune model of myalgic encephalomyelitis/chronic fatigue syndrome. Metab. Brain Dis. doi:10.1007/s11011-012-9324-8 (2012) (Epub ahead of print).
- Döring G . The role of neutrophil elastase in chronic inflammation. Am. J. Respir. Crit. Care Med.150(6 Pt 2) , S114–S117 (1994).
- Meeus M , NijsJ, McGregorN et al. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. In Vivo 22(1) , 115–122 (2008).
- Maes M , TwiskF, KuberaM et al. Evidence for inflammation and activation of cell-mediated immunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J. Affect. Disord. 136(3) , 933–939 (2012).
- Brenu EW , van Driel ML, Staines DR et al. Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J. Transl. Med.9 , 81 (2011).
- Maes M , MihaylovaI, LeunisJC. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro. Endocrinol. Lett.27(5) , 615–621 (2006).
- Maes M , TwiskF. Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO & NS) pathways may explain cardiovascular disorders in ME/CFS. Neuroendocrinol. Lett.30(6) , 677–693 (2009).
- Heresi GA , StollerJL. Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin. Biol. Ther.8(4) , 515–526 (2008).
- Pott GB , ChanED, DinarelloCA et al. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J. Leukoc. Biol. 85(5) , 886–895 (2009).
- Chan ED , PottGB, SilkfoffPE et al. Alpha-1-antitrypsin inhibits nitric oxide production. J. Leukoc. Biol. 92(6) , 1251–1260 (2012).
- Koulmanda M , BhasinM, HoffmanL et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl Acad. Sci. USA 105(42) , 16242–16247 (2008).
- American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med.168(7) , 818–900 (2003).
- Alegre C , BarcelóM, JardíR et al. Alpha 1-antitrypsin in fibromyalgia: results of a randomized, placebo-controlled, double-blind and crossover pilot trial. Musculoskeletal Care 10(3) , 178–183 (2012).
- Cho HJ , HotopfM, WesselyS. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom. Med.67(2) , 301–313 (2005).